A double-blind, placebo-controlled, multicenter, multinational phase III study to evaluate the safety and efficacy of sarizotan HCl 1 mg b.i.d [twice daily] in patients with Parkinson's disease suffering from treatment-associated dyskinesia

Trial Profile

A double-blind, placebo-controlled, multicenter, multinational phase III study to evaluate the safety and efficacy of sarizotan HCl 1 mg b.i.d [twice daily] in patients with Parkinson's disease suffering from treatment-associated dyskinesia

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2013

At a glance

  • Drugs Sarizotan (Primary)
  • Indications Drug-induced dyskinesia; Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms PADDY-1
  • Most Recent Events

    • 26 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top